Amarantus BioSciences Holdings struck a deal with Anavex Life Sciences to provide biomarker test services for the company's Alzheimer's drug candidates, a major win for Amarantus as it looks to expand the reach of its blood diagnostic test.
Israel's Pocared Diagnostics announced that it has raised $15 million in milestone-based funding as it attempts to commercialize its culture-free, computer-based diagnostic platform for bacterial identification and another for analysis of biological particles.
Trovagene, developer of a urine-based cancer diagnostic, announced last week plans to sell 4,444,444 shares of common stock for $20 million. The San Diego-based company makes technology for detecting cell-free DNA and RNA resulting from diseased cell death in the urine of cancer patients.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
Researchers at Florida's Moffitt Cancer Center are gaining deeper insight into the biological processes going on inside a tumor in an effort to battle cancer more effectively. They've developed a new technique to analyze specific protein complexes in cancer specimens.
Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor.
A new study presented at the Radiological Society of North America highlighted changes in brain connections that could be spotted in an MRI and may offer an imaging biomarker for early Alzheimer's.
Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
Virginia Tech researchers believe they've found a possible biomarker to help detect a rare genetic disease known as severe combined immunodeficiency, or SCID, which leaves patients needing to avoid all human contact and breathe filtered air in order to survive.
Biocept forged a partnership deal with a competitor that aims to build an enhanced molecular diagnostics test for circulating tumor cells in the blood. Success could breed a more precise test that aids patient diagnoses and drug development in equal measure.